NO137205C - Analogifremgangsm}te for fremstilling av piperazinpyrimidiner med terapeutisk virkning. - Google Patents

Analogifremgangsm}te for fremstilling av piperazinpyrimidiner med terapeutisk virkning.

Info

Publication number
NO137205C
NO137205C NO3260/73A NO326073A NO137205C NO 137205 C NO137205 C NO 137205C NO 3260/73 A NO3260/73 A NO 3260/73A NO 326073 A NO326073 A NO 326073A NO 137205 C NO137205 C NO 137205C
Authority
NO
Norway
Prior art keywords
pyrimidines
piperazine
preparation
therapeutic effect
analogical procedure
Prior art date
Application number
NO3260/73A
Other languages
English (en)
Norwegian (no)
Other versions
NO326073L (ja
NO137205B (no
Inventor
Gerard Loiseau
Georges Mattioda
Rene Millischer
Pierre Obellianne
Original Assignee
Ugine Kuhlmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ugine Kuhlmann filed Critical Ugine Kuhlmann
Publication of NO326073L publication Critical patent/NO326073L/no
Publication of NO137205B publication Critical patent/NO137205B/no
Publication of NO137205C publication Critical patent/NO137205C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO3260/73A 1973-07-06 1973-08-16 Analogifremgangsm}te for fremstilling av piperazinpyrimidiner med terapeutisk virkning. NO137205C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7324874A FR2257294B1 (ja) 1973-07-06 1973-07-06

Publications (3)

Publication Number Publication Date
NO326073L NO326073L (ja) 1975-02-03
NO137205B NO137205B (no) 1977-10-10
NO137205C true NO137205C (no) 1978-01-18

Family

ID=9122191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO3260/73A NO137205C (no) 1973-07-06 1973-08-16 Analogifremgangsm}te for fremstilling av piperazinpyrimidiner med terapeutisk virkning.

Country Status (10)

Country Link
JP (1) JPS5849548B2 (ja)
BE (1) BE803803A (ja)
CH (1) CH582171A5 (ja)
DE (1) DE2342880A1 (ja)
ES (1) ES418113A1 (ja)
FR (1) FR2257294B1 (ja)
GB (1) GB1434544A (ja)
LU (1) LU68263A1 (ja)
MX (1) MX2978E (ja)
NO (1) NO137205C (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605319A (nl) * 1975-05-23 1976-11-25 Mar Pha Etu Expl Marques Werkwijze ter bereiding van een geneesmiddel, zo gevormd geneesmiddel en werkwijze ter bereiding van geschikte geneeskrachtige verbindingen.
FR2417507A2 (fr) * 1977-07-28 1979-09-14 Ugine Kuhlmann Diamino-2,4 (ou -4,6) methylthio-5 pyrimidines herbicides
JPS54159877A (en) * 1978-06-07 1979-12-18 Matsushita Electronics Corp Detection method for semiconductor substrate position and break
FR2503162A1 (fr) * 1981-04-07 1982-10-08 Pharmindustrie Nouveaux derives de piperazino-2 pyrimidine, procedes pour leur preparation et leur utilisation comme medicaments ou comme intermediaires pour la fabrication de medicaments
JPS6177335A (ja) * 1984-09-25 1986-04-19 Kazumichi Kimura 半導体ペレツト不良マ−ク検出装置
IT1191845B (it) * 1986-01-20 1988-03-23 Dompe Farmaceutici Spa Alchiloli derivati farmacologicamente attivi
JPH02114936U (ja) * 1989-03-03 1990-09-14

Also Published As

Publication number Publication date
LU68263A1 (ja) 1973-10-24
MX2978E (es) 1980-01-17
NO326073L (ja) 1975-02-03
ES418113A1 (es) 1976-03-16
FR2257294B1 (ja) 1977-07-01
DE2342880A1 (de) 1975-01-30
NO137205B (no) 1977-10-10
BE803803A (fr) 1974-02-20
GB1434544A (en) 1976-05-05
JPS5025578A (ja) 1975-03-18
CH582171A5 (ja) 1976-11-30
FR2257294A1 (ja) 1975-08-08
JPS5849548B2 (ja) 1983-11-05

Similar Documents

Publication Publication Date Title
NO145273C (no) N-formyl-alfa-l-aspartyl-l-fenylalanin for anvendelse til fremstilling av alfa-l-aspartyl-l-fenylalaninalkylestere
SE423631B (sv) Forfarande for framstellning av oxaalhyl-dialkylxantiner
SE390819B (sv) Analogiforfarande for framstellning av piperazinyl-propyl-1,2,4-triazolinderivat
SE7710599L (sv) Forfarande for framstellning av bensisoxazoler
FI55846B (fi) Foerfarande foer framstaellning av 8-azapurin-5-onderivat med terapeutisk anvaendning
NO740606L (no) Analogifremgangsmåte til fremstilling av terapeutisk virksomme 3-klor-7-alfa-amino-acylcefalosporinforbindelser.
SE407575B (sv) Forfarande for framstellning av 1,3-dioxanderivat med terapentisk verkan
SE413244B (sv) Forfarandefor framstellning av bensopyraner med analgetisk verkan
SE396388B (sv) Analogiforfrande for framstellning av 2,3-dihydro-oxo-imidazo-/1,2-a/pyrimidiner
NO137387C (no) Analogifremgangsm}te til fremstilling av 5-metyltiopyrimidiner med terapeutisk virkning
NO146596C (no) Fremgangsmaate for fremstilling av 6-deoksytetracykliner
NO790627L (no) Fremgangsmaate for fremstilling av hydroksyalkylxantiner
SE417601B (sv) Forfarande for framstellning av amidinokarbamider
NO137205C (no) Analogifremgangsm}te for fremstilling av piperazinpyrimidiner med terapeutisk virkning.
NO843825L (no) Fremgangsmaate for fremstilling av 6-deoksytetracyklin
SE7608956L (sv) Forfarande for framstellning av 2-(fenoxialkyltio)-5-nitroimidazoler
SE402456B (sv) Analogiforfarande for framstellning av fenyletylaminderivat med anorexigen aktivitet
NO136574C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive pyrimidinderivater.
NO740607L (no) Analogifremgangsmåte til fremstilling av terapeutisk virksomme 7-acylamino-3-halogen-cefalosporinforbindelser.
SE398501B (sv) Analogiforfarande for framstellning av 1,4-bensodiazepinderivat
SE409994B (sv) Forfarande for framstellning av amidinokarbamider
NO140104C (no) Analogifremgangsmaate til fremstilling av 17beta-hydroksy-16,16-dimetylestr-4-en-3-on med terapeutisk aktivitet
NO139125C (no) Analogifremgangsmaate for fremstilling av cykloheksantetrolderivater
DK136249C (da) Analogifremgangsmade til fremstilling af xanthenderivater
NO140010C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 6-substituerte 3-karbetoksyhydrazinopyridaziner